SOURCE: Equity News Circuit

Equity News Circuit

May 17, 2013 08:15 ET

Free Research Reports on EGLE, HALO, NTES and TSRO Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwired - May 17, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Eagle Bulk Shipping Inc. (NASDAQ: EGLE) shares soared 53.93 percent on volume of 12.8 million shares traded to close at $5.48 a share. The company surprised Wall Street with a profit of $1.4 million, or $0.08 per share, for the first quarter of 2013, compared to a loss of $17.4 million, or $1.11 per share, in the year ago quarter.

Find out more about Eagle Bulk Shipping including full access to the free equity report at: www.BedfordReport.com/EGLE

Halozyme Therapeutics, Inc. (NASDAQ: HALO) shares surged 18.40 percent on nearly five times the average daily volume Thursday to close at $7.98 a share. The company reported data from a clinical trial of its pancreatic cancer drug, PEGPH20, showed it may make tumors more vulnerable to therapy.

Find out more about Halozyme Therapeutics including full access to the free equity report at: www.BedfordReport.com/HALO

NetEase, Inc. (NASDAQ: NTES) shares declined 3.89 percent on volume of nearly 1.0 million shares traded Thursday to close at $58.07 a share. The company reported revenues of RMB2.3 billion (US$363.6 million) for the first quarter of 2013, an increase of 12.7 percent when compared to the year ago quarter.

Find out more about NetEase including full access to the free equity report at: www.BedfordReport.com/NTES

TESARO Inc. (NASDAQ: TSRO) shares spiked 14.09 percent on volume of nearly 1.0 million shares traded to close at $35.88 a share. The company announced that it will present final results from a Phase 1 trial of niraparib at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

Find out more about TESARO including full access to the free equity report at: www.BedfordReport.com/TSRO

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information